ROIV position history
The shares of Roivant Sciences (ROIV) that DME Capital Management reported in each quarter’s 13F.
Shares held by quarter
New Add Reduce Exit
- 2024 Q1: 4,190,490 shares, $44M, 2.0% of portfolio
- 2024 Q2: 4,810,960 shares, $51M, 2.5% of portfolio, Add +14.8%
- 2024 Q3: 5,308,040 shares, $61M, 2.5% of portfolio, Add +10.3%
- 2024 Q4: 5,271,067 shares, $62M, 3.2% of portfolio, Reduce −0.7%
- 2025 Q1: 5,441,167 shares, $55M, 2.8% of portfolio, Add +3.2%
- 2025 Q2: 4,551,057 shares, $51M, 2.2% of portfolio, Reduce −16.4%
- 2025 Q3: 2,275,529 shares, $34M, 1.4% of portfolio, Reduce −50.0%
- 2025 Q4: 2,069,309 shares, $45M, 1.6% of portfolio, Reduce −9.1%
- 2026 Q1: 2,152,669 shares, $60M, 1.9% of portfolio, Add +4.0%
- 2026 Q2: 2,152,669 shares, $76M, 1.9% of portfolio
- 2026 Q3: 1,131,747 shares, $41M, 1.2% of portfolio, Reduce −47.4%
| Holdings date | Value | % of holdings | Shares | Filing date | All 13F holders |
|---|